Pellagra-like condition is xeroderma pigmentosum/Cockayne syndrome complex and niacin confers clinical benefit

Hijazi, H, Salih, MA, Hamad, MHA, Hassan, HH, Salih, SBM, Mohamed, KA, Mukhtar, MM, Karrar, ZA, Ansari, S, Ibrahim, N, others: Pellagra-like condition is xeroderma pigmentosum/Cockayne syndrome complex and niacin confers clinical benefit. In: Clinical genetics, 87 (1), pp. 56–61, 2015.

Abstract

An extremely rare pellagra-like condition has been described, which was partially responsive to niacin and associated with a multisystem involvement. The condition was proposed to represent a novel autosomal recessive entity but the underlying mutation remained unknown for almost three decades. The objective of this study was to identify the causal mutation in the pellagra-like condition and investigate the mechanism by which niacin confers clinical benefit. Autozygosity mapping and exome sequencing were used to identify the causal mutation, and comet assay on patient fibroblasts before and after niacin treatment to assess its effect on DNA damage. We identified a single disease locus that harbors a novel mutation in ERCC5, thus confirming that the condition is in fact xeroderma pigmentosum/Cockayne syndrome (XP/CS) complex. Importantly, we also show that the previously described dermatological response to niacin is consistent with a dramatic protective effect against ultraviolet-induced DNA damage in patient fibroblasts conferred by niacin treatment. Our findings show the power of exome sequencing in reassigning previously described novel clinical entities, and suggest a mechanism for the dermatological response to niacin in patients with XP/CS complex. This raises interesting possibilities about the potential therapeutic use of niacin in XP.

BibTeX (Download)

@article{hijazi2015pellagra,
title = {Pellagra-like condition is xeroderma pigmentosum/Cockayne syndrome complex and niacin confers clinical benefit},
author = {Hijazi, H and Salih, MA and Hamad, MHA and Hassan, HH and Salih, SBM and Mohamed, KA and Mukhtar, MM and Karrar, ZA and Ansari, S and Ibrahim, N and others},
url = {http://onlinelibrary.wiley.com/doi/10.1111/cge.12325/fullhttp://meduofk.net/wp-content/uploads/2015/11/Hijazi_et_al-2015-Clinical_Genetics.pdf},
doi = {10.1111/cge.12325},
year  = {2015},
date = {2015-01-01},
journal = {Clinical genetics},
volume = {87},
number = {1},
pages = {56--61},
publisher = {Wiley Online Library},
abstract = {An extremely rare pellagra-like condition has been described, which was partially responsive to niacin and associated with a multisystem involvement. The condition was proposed to represent a novel autosomal recessive entity but the underlying mutation remained unknown for almost three decades. The objective of this study was to identify the causal mutation in the pellagra-like condition and investigate the mechanism by which niacin confers clinical benefit. Autozygosity mapping and exome sequencing were used to identify the causal mutation, and comet assay on patient fibroblasts before and after niacin treatment to assess its effect on DNA damage. We identified a single disease locus that harbors a novel mutation in ERCC5, thus confirming that the condition is in fact xeroderma pigmentosum/Cockayne syndrome (XP/CS) complex. Importantly, we also show that the previously described dermatological response to niacin is consistent with a dramatic protective effect against ultraviolet-induced DNA damage in patient fibroblasts conferred by niacin treatment. Our findings show the power of exome sequencing in reassigning previously described novel clinical entities, and suggest a mechanism for the dermatological response to niacin in patients with XP/CS complex. This raises interesting possibilities about the potential therapeutic use of niacin in XP.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}